Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 375 of 2873 entries
View as:

Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003714 Org: User:
Start: - End: - Due: -

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06066359 Org: User:
Start: 11/30/23 End: 08/31/28 Due: 08/31/29

Prophylactic Lymphovenous Bypass Procedure Following Inguinal Lymphadenectomy: A Prospective Observational Study

Phase: N/A Priority: Normal
NCT ID: NCT05992909 Org: User:
Start: 08/02/23 End: 08/01/27 Due: 08/01/28

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase: N/A Priority: Normal
NCT ID: NCT03065387 Org: User:
Start: 10/31/17 End: 10/01/25 Due: 10/01/26

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02419495 Org: User:
Start: 06/26/15 End: 09/16/24 Due: 09/16/25

Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05100095 Org: User:
Start: 12/14/21 End: 09/01/28 Due: 09/01/29

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06285890 Org: User:
Start: 05/20/24 End: 12/31/29 Due: 12/31/30

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Phase: N/A Priority: Normal
NCT ID: NCT06762808 Org: User:
Start: 06/01/25 End: 12/31/28 Due: 12/31/29

Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia

Phase: N/A Priority: Normal
NCT ID: NCT00503854 Org: User:
Start: 05/31/07 End: 04/05/18 Due: 04/05/19

Telephone Counseling-Mailed Materials Versus Internet Interventions in Overweight Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT01311856 Org: User:
Start: 03/31/11 End: 03/31/21 Due: 03/31/22

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)

Phase: N/A Priority: Normal
NCT ID: NCT02152254 Org: User:
Start: 05/13/14 End: 12/31/30 Due: 12/31/31

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Phase: N/A Priority: Normal
NCT ID: NCT06327100 Org: User:
Start: 08/01/24 End: 05/01/31 Due: 05/01/32

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Phase: N/A Priority: Normal
NCT ID: NCT06754501 Org: User:
Start: 04/11/25 End: 07/01/29 Due: 07/01/30

Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03637816 Org: User:
Start: 11/27/18 End: 12/31/26 Due: 12/31/27

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06959550 Org: User:
Start: 10/01/25 End: 07/01/30 Due: 07/01/31

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT05845307 Org: User:
Start: 10/31/25 End: 06/01/28 Due: 06/01/29

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT04744116 Org: User:
Start: 02/17/21 End: 03/15/26 Due: 03/15/27

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Phase: N/A Priority: Normal
NCT ID: NCT01479179 Org: User:
Start: 11/30/12 End: - Due: -

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

Phase: N/A Priority: Normal
NCT ID: NCT03896646 Org: User:
Start: 10/10/19 End: 09/30/26 Due: 09/30/27

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05636111 Org: User:
Start: 07/12/23 End: 07/31/26 Due: 07/31/27

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Phase: N/A Priority: Normal
NCT ID: NCT05834244 Org: User:
Start: 10/26/23 End: 06/30/28 Due: 06/30/29

Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00832715 Org: User:
Start: 04/30/09 End: 07/31/16 Due: 07/31/17

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01738139 Org: User:
Start: 02/19/13 End: 12/13/23 Due: 12/13/24

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00038545 Org: User:
Start: 05/18/01 End: 04/27/04 Due: 04/27/05

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

Phase: N/A Priority: Normal
NCT ID: NCT01253460 Org: User:
Start: 08/22/11 End: 02/13/19 Due: 02/13/20